Tris-GalNAc-COOH serves a pivotal role in the innovative realm of lysosomal targeting chimera (LYTAC) technology. This specialized compound is engineered as an effective asialoglycoprotein receptor (ASGPR) ligand. This trivalent β-GalNAc Ligand has a discrete, monodisperse, carboxyl-functionalized pentaethyleneglycol (PEG5) linker/spacer. This structure is specifically tailored for attachment to a targeted protein ligand, paving the way for the creation of advanced therapeutic strategies. These strategies exploit the mechanism of guiding molecules directly to lysosomes, facilitating their degradation. The utility of Tris-GalNAc-COOH in this cutting-edge research underscores its significance in the quest for targeted treatment modalities.